M. Seibel, V. Naganathan, I. Barton
Dec 16, 2003
Citations
1
Influential Citations
104
Citations
Quality indicators
Journal
Journal of Bone and Mineral Research
Abstract
It is unclear whether the antifracture efficacy of bisphosphonates depends on pretreatment bone turnover. We analyzed the risedronate phase III clinical programs using the urinary excretion of deoxypyridinoline (uDPD) as an index of pretreatment bone resorption rates. Risedronate reduced incident vertebral fractures in women with postmenopausal osteoporosis independent from pretreatment bone resorption.